Quest launches "quicker" HIV tropism test in US
This article was originally published in Clinica
Quest Diagnostics has launched its HIV-1 coreceptor tropism test, to determine whether HIV patients will respond to CCR5-targeting drugs, as a lab service in the US. The Madison, New Jersey firm claims its test provides results in "half the time of the nearest competing test", Monogram Biosciences' Trofile (seven versus 14 days). Both tests identify which coreceptor a patient's HIV virus uses to enter human CD4 cells – CCR5, CXCR4, or a combination. This is known as the patient's "tropism". CCR5 antagonists, such as Pfizer's Selzentry (maraviroc), block the CCR5 coreceptor and therefore HIV entry, but only in CCR5-tropic patients. Trofile was launched in the US in August 2007.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.